Skip to main content
SHIJIAZHUANG YILING PHARMACEUTICAL CO.,LTD logo

SHIJIAZHUANG YILING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002603 ISIN · CNE1000015S0 LEI · 300300MXXUF4JUKD5G32 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2026-05-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002603

About SHIJIAZHUANG YILING PHARMACEUTICAL CO.,LTD

https://www.yiling.cn

Shijiazhuang Yiling Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of modern Traditional Chinese Medicine (TCM). The company operates based on the "Collateral Disease Theory," a proprietary academic framework used to guide the development of innovative treatments. Its product portfolio focuses on cardiovascular and cerebrovascular diseases, respiratory ailments, and diabetes. Key products include Lianhua Qingwen capsules for influenza and viral infections, Tongxinluo capsules for coronary heart disease, and Shensong Yangxin capsules for arrhythmia. The company maintains a vertically integrated business model encompassing medicinal herb cultivation, scientific research, and large-scale production facilities. Yiling Pharmaceutical emphasizes evidence-based medicine, conducting clinical trials to validate the efficacy of its TCM formulations for international markets.

Recent filings

Filing Released Lang Actions
第九届董事会第一次会议决议公告
Board/Management Information Classification · 96% confidence The document is an announcement by the company’s board detailing the resolutions from the first meeting of the ninth board of directors, including the election of the board chair and appointments of board committees and senior management positions. It announces changes to the company’s board and senior management. This fits the definition of Board/Management Information (MANG).
2026-05-27 Chinese
北京国枫律师事务所关于石家庄以岭药业股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a lawyer’s legal opinion letter on the convening and conclusion of the 2025 Annual General Meeting, including detailed vote counts for each resolution. It serves as an official disclosure of shareholder voting results at an AGM. This aligns with Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-27 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the results of resolutions approved at the company’s 2025 annual general meeting, detailing vote counts for each proposal and confirming the legal validity of the meeting. This fits the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-27 Chinese
关于全资孙公司收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement by Shijiazhuang Yiling Pharmaceutical Co., Ltd. informing investors that its wholly-owned subsidiary received an approval notice from the National Medical Products Administration for a chemical raw material drug. It is a regulatory announcement of an approval event, not an earnings release, board change, transaction, or detailed report. It does not solicit proxies or provide financial statements. This falls under the general “Regulatory Filings” category for miscellaneous compliance and announcement filings. Therefore, it should be classified as RNS.
2026-05-14 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official announcement of the resolutions and voting outcomes of the company’s first extraordinary shareholders’ meeting (临时股东会), detailing attendance, voting methods, and the vote tallies on the proposed amendment to the Articles of Association. This corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-13 Chinese
经营决策管理制度（2025年12月修订）
Governance Information Classification · 95% confidence The document is titled '经营决策管理制度' which translates to 'Management Decision-Making System' and details the company's internal rules and procedures for major business decisions, including decision scope, authority, execution, supervision, and legal responsibilities. It references company law, company articles, and regulatory requirements but does not contain financial statements or results. It is a governance-related document outlining internal management and decision-making processes rather than a financial report or announcement. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and contains substantive content, not just an announcement or certification.
2025-12-05 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.